Journal September 17, 2026 6 min read

How to Reconstitute BPC-157

BPC-157 is a synthetic pentadecapeptide. This page covers its formal identifiers, the pathways studied, and what the evidence says about reconstitution and handling for laboratory research use.

peptides-pro Editorial

How to reconstitute BPC-157

BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment, studied preclinically for cytoprotective and regenerative activity across multiple organ systems [3]. It is also referred to as Body Protective Compound-157 or BPC 157. The evidence block does not provide a sequence, molecular formula, or molecular weight for this compound, so none are stated here. Reconstitution for laboratory use means dissolving the lyophilised peptide in a suitable solvent to a defined working concentration; the evidence block does not specify a validated reconstitution protocol, solvent, or concentration for BPC-157, and no such protocol is invented on this page.

The work described in the evidence centres on nitric oxide signalling, angiogenesis, and acetylcholinesterase inhibition, among other pathways [2][4][8].

Research Studies

BPC-157 and tendon healing in a rat Achilles model

A study in rats evaluated BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses. The study used thirty-two male Sprague-Dawley rats [9]. This is an animal model; findings in rats are not evidence of the same effect in humans.

BPC-157 and rotator cuff repair in a human pilot trial

A randomised, double-blind, placebo-controlled pilot trial is investigating BPC-157 in patients undergoing arthroscopic rotator cuff repair (aRCR). Twenty patients are to be enrolled and randomly assigned to BPC-157 or saline placebo, with daily subcutaneous injections for 90 days following surgery, alongside standard postoperative care [1]. This is a registered trial; the evidence block does not report results. The same source notes that BPC-157 has shown regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury but had not been studied in formal human clinical trials at the time of registration [1].

BPC-157 and acetylcholinesterase inhibition in vitro

An in vitro study examined the inhibitory potential of BPC-157 and two hybrid analogs, CIARA-1 and CIARA-2, against acetylcholinesterase (AChE). The hybrids were designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme's active and peripheral binding sites. Enzyme kinetics were evaluated using a modified Ellman assay, and inhibition parameters were determined through Lineweaver-Burk analysis [2]. This is an enzyme assay, not a clinical study.

BPC-157 and vascular tone in human internal mammary artery

A study investigated the effects of BPC-157 on vascular tone in human internal mammary artery (IMA) rings and evaluated the contribution of endothelial nitric oxide signalling. Residual IMA segments were obtained from elective coronary artery bypass graft surgeries (n = 12) and dissected into endothelium-intact and endothelium-denuded preparations [8]. This is ex vivo human tissue work, not a clinical trial.

BPC-157 and tissue repair mechanisms in preclinical models

A review reports that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in diverse preclinical models. The same review reports reduced inflammatory cytokine activity, improved microvascular integrity, and effects on pain modulation through peripheral and dopaminergic mechanisms. Animal data were described as indicating favourable safety and pharmacokinetic profiles [4]. These findings are from preclinical models.

BPC-157 and biopharmaceutical development status

A review evaluating BPC-157 from a biopharmaceutical and drug development perspective states that despite over three decades of preclinical research, its pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. The review examines physicochemical and pharmacokinetic properties and formulation challenges across routes of administration [3]. This describes the development status of the compound, not a reconstitution protocol.

BPC-157 and hydrogel formulation

A study fabricated and characterised a CH/BPC composite hydrogel and examined its physicochemical properties. The formulation exhibited a porous structure, analysed through scanning electron microscopy (SEM) and transmission electron microscopy [10]. This is a materials-characterisation study.

BPC-157 and expression in Bacillus licheniformis

A study reports stable expression of γ-glutamyltranspeptidase (GGT)-BPC157 and mScarlet-BPC157 in Bacillus licheniformis strain 2709 by chromosomal integration. Fermentation conditions were optimised using single-factor and orthogonal experiments to maximise yield, with optimal conditions including 2% inoculum, 40 g/L soybean peptone, and 80 [11]. This is a production study, not a reconstitution study.

BPC-157 and peptide availability in sexual medicine

A cross-sectional, state-level analysis of all 50 U.S. states and the District of Columbia compared state-level environments affecting access to peptide-based sexual medicine therapies using three reproducible proxy variables reflecting clinical factors [6]. This is a health-services analysis, not a laboratory study of BPC-157.

BPC-157 and orthobiologics in knee osteoarthritis

A review of orthobiologics in the treatment of knee osteoarthritis discusses regenerative therapies designed to treat orthopaedic conditions, including the use of autologous biological substances [7]. BPC-157 is not the focus of this review; it is cited here as context for the broader field.

BPC-157 and regenerative medicine review

A narrative review summarises current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, BPC-157, thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), and glycyl-L-histidyl-L-lysine copper (GHK-Cu) [12]. This is a review, not a primary study.

Comparison of evidence types

Evidence type	Model or population	What was reported
Animal study	Male Sprague-Dawley rats	Achilles tendon healing assessed by biomechanical, histopathological, histochemical, and immunohistochemical analyses [9]
Registered human trial	Patients undergoing arthroscopic rotator cuff repair (n = 20 planned)	Randomised, double-blind, placebo-controlled pilot; daily subcutaneous injections for 90 days; results not reported in the evidence block [1]
In vitro enzyme assay	Acetylcholinesterase	Inhibition parameters determined by modified Ellman assay and Lineweaver-Burk analysis [2]
Ex vivo human tissue	Human internal mammary artery rings (n = 12)	Effects on vascular tone and endothelial nitric oxide signalling [8]
Review	Preclinical models	Angiogenesis, collagen synthesis, fibroblast activity, nitric oxide modulation, inflammatory cytokine activity, microvascular integrity, pain modulation [4]
Review	Drug development	No approved formulation, no validated dosing regimen, no completed Phase II clinical trial [3]

If you are reading this for personal health reasons

This material is sold for laboratory research use only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.